• Explore /
  • Poster
  • / A first-in-human dose escalation study of PEGylated recombinant human IL-10 (AM0010) in advanced solid tumors.

A first-in-human dose escalation study of PEGylated recombinant human IL-10 (AM0010) in advanced solid tumors.

Abstract Poster

Authors

null

Jeffrey R. Infante

Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN

Jeffrey R. Infante , Aung Naing , Kyriakos P. Papadopoulos , Karen A. Autio , Patrick Alexander Ott , Deborah Jean Lee Wong , Gerald Steven Falchook , Manish R. Patel , Shubham Pant , Melinda Whiteside , Johanna C. Bendell , Todd Michael Bauer , Filip Janku , Milind M. Javle , David S. Hong , Martin Oft

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research

Sub Track

Immunotherapy and Biologic Therapy

Clinical Trial Registration Number

NCT02009449

Citation

J Clin Oncol 33, 2015 (suppl; abstr 3017)

DOI

10.1200/jco.2015.33.15_suppl.3017

Abstract #

3017

Poster Bd #

343

Abstract Disclosures

Similar Posters

First Author: Jennifer L. Spratlin

First Author: Anwaar Saeed

First Author: Shunsuke Kondo

Poster

2022 ASCO Annual Meeting

Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors.

Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors.

First Author: Qing Zhou